Muscle weakness in mechanically ventilated patients with severe asthma

Area of Science:

• Critical Care Medicine
• Neurology
• Pulmonology

Background:

• Mechanical ventilation for severe asthma can lead to acute myopathy and diffuse muscle weakness.
• The roles of corticosteroids and neuromuscular paralysis in causing this myopathy are debated.
• The influence of neuromuscular blocking agent chemical structure on myopathy risk is unclear.

Purpose of the Study:

• To determine the incidence of muscle weakness in severe asthma patients receiving corticosteroids with or without neuromuscular paralysis.
• To assess the impact of paralysis duration on muscle weakness development.
• To compare the risk of weakness associated with atracurium versus aminosteroid paralytic agents.

Main Methods:

• Retrospective cohort study of 107 patients with severe asthma requiring mechanical ventilation.
• Comparison of muscle weakness incidence between corticosteroid-only group and corticosteroid plus neuromuscular paralysis group.
• Analysis of paralysis duration and type of neuromuscular blocking agent (atracurium vs. aminosteroids).

Main Results:

• Neuromuscular paralysis combined with corticosteroids significantly increased muscle weakness incidence (20/69) compared to corticosteroids alone (0/38).
• Patients developing weakness were paralyzed significantly longer (3.4 days) than those without weakness (0.6 days).
• Weakness incidence was similar between atracurium and aminosteroid paralytic agents, with 18/20 weak patients paralyzed >24 hours.

Conclusions:

• Prolonged neuromuscular paralysis in severe asthma patients on corticosteroids poses a significant risk for muscle weakness.
• The risk of developing muscle weakness is not reduced by using atracurium compared to aminosteroid agents.
• Clinical management should consider the risks associated with prolonged paralysis in this patient population.